INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2006/306800

A. CLASSIFICATION OF SUBJECT MATTER C12N15/09(2006.01), A61K39/395(2006.01), CO According to International Patent Classification (IPC) or to both national class B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification 12N15/00-15/90, A61K39/395, C07K1/00-19/0	estification and IPC cation symbols) 0 at such documents are included in the symbols yo Shinan Toroku Koho 1 Jitsuyo Shinan Koho			
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classifi	cation symbols) of at such documents are included in the syo Shinan Toroku Koho u Jitsuyo Shinan Koho	1996-2006		
Minimum documentation searched (classification system followed by classifi	at such documents are included in th yo Shinan Toroku Koho ı Jitsuyo Shinan Koho	1996-2006		
Minimum documentation searched (classification system followed by classific C12N15/00-15/90, A61K39/395, C07K1/00-19/0	at such documents are included in th yo Shinan Toroku Koho ı Jitsuyo Shinan Koho	1996-2006		
	yo Shinan Toroku Koho ı Jitsuyo Shinan Koho	1996-2006		
, ·				
Electronic data base consulted during the international search (name of data BIOSIS/MEDLINE/WPIDS(STN), Science Dire				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category* Citation of document, with indication, where appropr	iate, of the relevant passages	Relevant to claim No.		
Y KIPRIYANOV SM. et al., Effect o on the activity of bacterially bispecific single-chain Fv anti J.Mol.Biol., 2003, Vol.330, No. 99 to 111	produced bodies.,	1-44		
Y KRIANGKUM J. et al., Bispecific single chain recombinant antiboen Eng., 2001, Vol.18, No.2, pages	dies., Biomol.	1-44		
T cell effector function by rec bispecific single chain Fv (ant idiotype) induces long-term sur murine BCL1 lymphoma model., J.	DE JONGE J. et al., In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model., J.Immunol., 1998, Vol.161, No.3, pages 1454 to 1461			
Year There documents are listed in the continuation of Box C. See patent family annex. See patent family annex.				
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date and not in conflict with the application but cited to und the principle or theory underlying the invention cate considered novel or cannot be considered to involve an step when the document is taken alone "C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search "Date of mailing of the international search report		ion but cited to understand rention aimed invention cannot be red to involve an inventive cannot be p when the document is ocuments, such combination art maly		
28 April, 2006 (28.04.06) Name and mailing address of the ISA/ Aut	16 May, 2006 (16.09	5.06)		
Japanese Patent Office Telephone No.				

Form PCT/ISA/210 (second sheet) (April 2005)

COPY SUBMITTED IN IDS

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP2006/306800

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MALLENDER WD. et al., Construction, expression, and activity of a bivalent bispecific single-chain antibody., J.Biol.Chem., 1994, Vol.269, No.1, pages 199 to 206	1-44
Y	MACK M. et al., A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity., Proc.Natl.Acad.Sci.USA., 1995, Vol.92, No.15, pages 7021 to 7025	3,4,7,13, 23-43
Y	1995, Vol.92, No.15, pages 7021 to 7025 ORITA, T. et al., A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor., Blood, 15 January, 2005 (15.01.05), Vol.105, No.2, pages 562 to 566	3,4,7,13, 23-43

Form PCT/ISA/210 (continuation of second sheet) (April 2005)

国際調査報告

国際出願番号 PCT/JP2006/306800

A. 発明の属する分野の分類(国際特許分類(IPC))

Int.Cl. C12N15/09(2006.01), A61K39/395(2006.01), C07K1/14((2006.01), C07K16/46(2006.01)

B. 調査を行った分野

調査を行った最小限資料(国際特許分類(IPC))

Int.Cl. C12N15/00-15/90, A61K39/395, C07K1/00-19/00

最小限資料以外の資料で調査を行った分野に含まれるもの

日本国実用新案公報

1922-1996年

日本国公開実用新案公報

1971-2006年

日本国実用新案登録公報

1996-2006年

日本国登録実用新案公報

1994-2006年

国際調査で使用した電子データベース(データベースの名称、調査に使用した用語)

BIOSIS/MEDLINE/WPIDS(STN), Science Direct, JSTPlus(JDream2), PubMed

C. 関連すると認められる文献			
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号	
Y	KIPRIYANOV SM, et al., Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies., J Mol Biol., 2003, vol.330, no.1, p.99-111	1-44	
Y	KRIANGKUM J, et al., Bispecific and bifunctional single chain recombinant antibodies., Biomol Eng., 2001, vol.18, no.2, p.31-40	1-44	

▽ C欄の続きにも文献が列挙されている。

プ パテントファミリーに関する別紙を参照。

- * 引用文献のカテゴリー
- 「A」特に関連のある文献ではなく、一般的技術水準を示す もの
- 「E」国際出願日前の出願または特許であるが、国際出願日 以後に公表されたもの
- 「L」優先権主張に疑義を提起する文献又は他の文献の発行 日若しくは他の特別な理由を確立するために引用す る文献(理由を付す)
- 「O」ロ頭による開示、使用、展示等に言及する文献
- 「P」国際出願日前で、かつ優先権の主張の基礎となる出願

- の日の後に公表された文献
- 「T」国際出願日又は優先日後に公表された文献であって 出願と矛盾するものではなく、発明の原理又は理論 の理解のために引用するもの
- 「X」特に関連のある文献であって、当該文献のみで発明 の新規性又は進歩性がないと考えられるもの
- 「Y」特に関連のある文献であって、当該文献と他の1以上の文献との、当業者にとって自明である組合せによって進歩性がないと考えられるもの
- 「&」同一パテントファミリー文献

国際調査を完了した日 28.04.2006 国際調査報告の発送日 16.05.2006 目際調査機関の名称及びあて先 特許庁審査官(権限のある職員) 4B 9358 日本国特許庁(ISA/JP) 小暮 道明 東京都千代田区霞が関三丁目4番3号 電話番号 03-3581-1101 内線 3448

COPY SUBMITTED IN IDS

国際調査報告

国際出願番号 PCT/JP2006/306800

C (続き). 関連すると認められる文献			
引用文献の カテゴリー*	引用文献名 及び一部の箇所が関連するときは、その関連する箇所の表示	関連する 請求の範囲の番号	
Y	DE JONGE J, et al., In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model., J Immunol., 1998, vol.161, no.3, p.1454-1461	1-44	
Y	MALLENDER WD, et al., Construction, expression, and activity of a bivalent bispecific single-chain antibody., J Biol Chem., 1994, vol.269, no.1, p.199-206	1-44	
Y	MACK M, et al., A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity., Proc Natl Acad Sci USA., 1995, vol.92, no.15, p.7021-7025	3, 4, 7, 13, 23-43	
Y	ORITA T,et al., A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor., Blood, 2005.01.15, vol.105, no.2, p.562-566	3, 4, 7, 13, 23-43	